Olivier Lambotte
A5085234192- HIV Research and Treatment
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- HIV/AIDS Research and Interventions
- Chronic Lymphocytic Leukemia Research
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- Autoimmune and Inflammatory Disorders Research
- Platelet Disorders and Treatments
- T-cell and B-cell Immunology
- Lymphoma Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Colorectal Cancer Treatments and Studies
- Systemic Lupus Erythematosus Research
- Immunodeficiency and Autoimmune Disorders
- Viral-associated cancers and disorders
- Blood groups and transfusion
- CAR-T cell therapy research
- Pneumocystis jirovecii pneumonia detection and treatment
- Lung Cancer Treatments and Mutations
- Hepatitis C virus research
- Renal Diseases and Glomerulopathies
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Drug-Induced Adverse Reactions
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
2016-2025
Infectious Disease Models and Innovative Therapies
2016-2025
Bicêtre Hospital
2016-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Inserm
2016-2025
CEA Paris-Saclay - Etablissement de Fontenay-aux-roses
2015-2025
Université Paris-Saclay
2016-2025
CEA Paris-Saclay
2020-2025
Hôpital Necker-Enfants Malades
2004-2024
Université Paris Cité
2024
Because it has no unique clinical, biologic, or histologic features, reactive hemophagocytic syndrome may be difficult to distinguish from other diseases such as severe sepsis hematologic malignancies. This study was undertaken develop and validate a diagnostic score for syndrome.A multicenter retrospective cohort of 312 patients who were judged by experts have (n = 162), not 104), in whom the diagnosis undetermined 46) used construct score, called HScore. Ten explanatory variables evaluated...
Combination antiretroviral therapy (cART) reduces HIV-associated morbidities and mortalities but cannot cure the infection. Given difficulty of eradicating HIV-1, a functional for HIV-infected patients appears to be more reachable short-term goal. We identified 14 HIV (post-treatment controllers [PTCs]) whose viremia remained controlled several years after interruption prolonged cART initiated during primary Most PTCs lacked protective HLA B alleles that are overrepresented in spontaneous...
<h3>Importance</h3> Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19). <h3>Objective</h3> To determine whether tocilizumab (TCZ) improves outcomes patients hospitalized moderate-to-severe COVID-19 pneumonia. <h3>Design, Setting, Particpants</h3> This cohort-embedded, investigator-initiated, multicenter, open-label, bayesian randomized clinical trial investigating moderate or severe requiring at least 3 L/min...
Some rare HIV-1-infected individuals, referred to as HIV controllers (HIC), have persistently undetectable plasma viral load in the absence of therapy. This control HIV-1 replication has been associated with a strong, multifunctional specific CD8(+) T cell response. However, no direct link between this immune response and viremia so far provided. We investigated parameters vitro susceptibility infection 11 HIC. found high frequencies HIV-specific cells. Interestingly, these cells expressed...
A number of open-label studies have suggested the potential benefit rituximab (RTX) in systemic lupus erythematosus (SLE). However, 2 recent randomized controlled trials (RCTs) RTX, primary end points were not met. We undertook this study to evaluate safety and efficacy RTX off-trial patients with SLE seen regular clinical practice.We analyzed prospective data from French AutoImmunity Rituximab (AIR) registry, which includes on autoimmune disorders treated RTX.One hundred thirty-six received...
Although immune checkpoint inhibitors (ICIs), such as anti-PD-1 (programmed cell death 1) or anti-PD-L1 1 ligand 1), have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists on the safety of resuming these treatments after an irAE.
To determine the spectrum of antiviral antibodies in HIV-1-infected individuals whom viral replication is spontaneously undetectable, termed HIV controllers (HICs).Multicenter French trial ANRS EP36 studying control HICs.Neutralizing Antibody (nAb) activities (neutralization assay, competition with broadly reactive monoclonal antibodies, and reactivity against MPER gp41 region), FcgammaR-mediated activities, antibody-dependent cell cytotoxicity (ADCC), as well autoantibody levels, were...
Patients with COVID-19 pneumonia have an excess of inflammation and increased concentrations cytokines including interleukin-1 (IL-1). We aimed to determine whether anakinra, a recombinant human IL-1 receptor antagonist, could improve outcomes in patients hospital mild-to-moderate pneumonia.In this multicentre, open-label, Bayesian randomised clinical trial (CORIMUNO-ANA-1), nested within the CORIMUNO-19 cohort, we recruited from 16 University hospitals France pneumonia, severe acute...
OBJECTIVES: The enteropathy associated with common variable immunodeficiency (CVID) is poorly characterized, and its possible relationships well-defined causes of enteropathy, such as celiac sprue (CS), remain debated. We aimed to assess the clinical histopathological features CVID. METHODS: medical files 50 CVID patients gastrointestinal symptoms were analyzed retrospectively. Histological, phenotypic, molecular analysis intestinal endoscopic specimens was centrally performed. RESULTS:...
Immune checkpoint inhibitors (ICIs) for cancer therapy frequently induce immune-related adverse effects (IRAEs). Therefore, most patients with preexisting autoimmune diseases have been excluded from clinical trials of ICIs. This study was undertaken to evaluate the safety and efficacy ICIs in disease cancer.A retrospective cohort conducted January 2017 2018 via 3 French national networks experts oncology autoimmunity. Adults who were receiving assessed occurrence flare disease, other IRAEs,...
Abstract The Fc region of HIV-1 Env-specific broadly neutralizing antibodies (bNAbs) is required for suppressing viraemia, through mechanisms which remain poorly understood. Here, we identify bNAbs that exert antibody-dependent cellular cytotoxicity (ADCC) in cell culture and kill HIV-1-infected lymphocytes natural killer (NK) engagement. These target the CD4-binding site, glycans/V3 V1/V2 loops on gp120, or gp41 moiety. landscape Env epitope exposure at surface sensitivity infected cells to...
<h3>Objectives</h3> Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death 1 (PD-1) have demonstrated improved survival for multiple cancers. However, these new drug classes led to increased immune-related adverse events (IrAE). Rheumatic IrAEs not been well described in clinical trials. We report here cases of rheumatoid arthritis (RA) polymyalgia rheumatica (PMR) occurring after ICI treatment. <h3>Methods</h3> This was a...
Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence these lack guidance for rheumatologists addressing them, a European League Against Rheumatism task force was convened to harmonise expert opinion regarding their identification management.First, group formulated research questions systematic literature review. Then, based on using consensus procedure, 4...
Two of the crucial aspects human immunodeficiency virus (HIV) infection are (i) viral persistence in reservoirs (precluding eradication) and (ii) chronic inflammation (directly associated with all-cause morbidities antiretroviral therapy (ART)-controlled HIV-infected patients). The objective present study was to assess potential involvement adipose tissue these two aspects. Adipose is composed adipocytes stromal vascular fraction (SVF); latter comprises immune cells such as CD4+ T...